GlassScriptPhysician profile
Varun K Bhalla
NPI 1568859007
$6,677.39
in general payments reported to CMS, 2019-2025
27 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $315 · 2023: $2,003 · 2024: $1,716 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,362.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,774.07 | 2022-2025 | Enbrel, Krystexxa, Evenity |
| Abbvie INC. | $1,645.66 | 2022-2025 | Rinvoq, Humira, Skyrizi |
| Ucb, INC. | $486.24 | 2022-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $388.02 | 2022-2025 | Tremfya |
| Glaxosmithkline, LLC. | $361.89 | 2023-2025 | Benlysta |
| Pfizer INC. | $324.05 | 2023-2025 | |
| Radius Health, INC. | $260.42 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $250.89 | 2022-2025 | |
| Genentech USA, INC. | $163.01 | 2023-2025 | Actemra, Rituxan |
| Astrazeneca Pharmaceuticals LP | $150.36 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $124.21 | 2024-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.11 | 2023-2025 | Ofev, Cyltezo, Jascayd |
| Monaghan Medical Corporation | $85.99 | 2023 | Aerobika |
| Fresenius Kabi USA, LLC | $73.15 | 2023-2025 | Idacio |
| Mallinckrodt Hospital Products INC. | $72.34 | 2024-2025 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $71.34 | 2022-2024 | Taltz, Zepbound |
| Abbott Laboratories | $64.11 | 2023 | Proclaim |
| Aurinia Pharma U.S., INC. | $59.88 | 2023-2025 | Lupkynis |
| Sandoz INC. | $38.87 | 2023-2025 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $33.44 | 2024 | Arcalyst |
| Fidia Pharma USA INC. | $26.96 | 2024 | Hymovis |
| Kowa Pharmaceuticals America, INC. | $22.21 | 2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $19.57 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $17.24 | 2023 | |
| Organon LLC | $17.21 | 2024 | |
| Depuy Synthes Sales INC. | $14.66 | 2024 | Orthovisc, Monovisc |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.